The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1364
ISSUE1364
May 16, 2011
Azilsartan Medoxomil (Edarbi) - The Eighth ARB
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Azilsartan Medoxomil (Edarbi) - The Eighth ARB
May 16, 2011 (Issue: 1364)
The angiotensin receptor blocker (ARB) azilsartan
medoxomil (Edarbi – Takeda) was recently approved
by the FDA for oral treatment of hypertension, either
alone or combined with other drugs. It is the eighth
ARB approved for this indication....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
